孕期母体贫血的优化管理可降低母体发病风险。
Antenatal Optimization of Maternal Anemia Leads to Decreased Risks of Maternal Morbidity.
作者信息
Smith Laura A, Young Brett C
机构信息
Beth Israel Deaconess Medical Center, Department of Maternal Fetal Medicine, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215 USA.
出版信息
Curr Obstet Gynecol Rep. 2023 Jun 3:1-7. doi: 10.1007/s13669-023-00366-7.
PURPOSE OF REVIEW
Our review focuses on the appropriate use of intravenous iron to increase the likelihood of achieving target hemoglobin levels prior to delivery to reduce maternal morbidity.
RECENT FINDINGS
Iron deficiency anemia (IDA) is a leading contributor to severe maternal morbidity and mortality. Prenatal treatment of IDA has been demonstrated to reduce the likelihood of adverse maternal outcomes. Recent investigations of intravenous iron supplementation have demonstrated superior efficacy and high tolerability for the treatment of IDA in the third trimester, compared against oral regimens. However, it is unknown whether this treatment is cost-effective, available to clinicians, or acceptable to patients.
SUMMARY
Intravenous iron is superior to the oral treatment of IDA; however, its use is limited by the lack of implementation data.
综述目的
我们的综述重点关注静脉铁剂的合理使用，以提高分娩前达到目标血红蛋白水平的可能性，从而降低孕产妇发病率。
最新发现
缺铁性贫血（IDA）是导致严重孕产妇发病和死亡的主要因素。已证明对IDA进行产前治疗可降低孕产妇不良结局的可能性。最近对静脉补铁的研究表明，与口服方案相比，在孕晚期治疗IDA具有更高的疗效和耐受性。然而，这种治疗是否具有成本效益、临床医生是否可用或患者是否接受尚不清楚。
总结
静脉铁剂优于IDA的口服治疗；然而，其应用因缺乏实施数据而受到限制。
Zotero 插件